Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||malignant glioma||not applicable||Sunitinib||Phase II||Actionable||In a Phase II clinical trial, Sutent (sunitinib) was well-tolerated in young patients with high grade glioma, but did not demonstrate sufficient anti-tumor activity as a single agent, with no patients achieving a sustained objective response (PMID: 27109549).||27109549|
|Unknown unknown||malignant glioma||not applicable||Sunitinib||Preclinical||Actionable||In a preclinical study, Sutent (sunitinb) induced cell death and decreased proliferation of glioma cells in culture (PMID: 25458015).||25458015|
|PubMed Id||Reference Title||Details|
|(25458015)||Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.||Full reference...|
|(27109549)||Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021.||Full reference...|